StockData
Vericel Corp logo

Vericel Corp (VCEL) stock

VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/30329% above fair value
$57.88+0.40 (+0.70%)

Close on Nov 17, 2026Market cap $2.96BP/E 137.8Yield –

Vericel operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Vericel's operating income for the twelve months ending Jun 30, 2026 was $18.24M, up 1428.5% year over year. For fiscal 2025 it was $11.04M, up 144.4% from the year before. The highest annual figure on record is $11.04M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.04M+144.4%
FY2024Dec 31, 2024$4.52M–
FY2023Dec 31, 2023-$6.46M–
FY2022Dec 31, 2022-$17.06M–
FY2021Dec 31, 2021-$7.85M-431.1%
FY2020Dec 31, 2020$2.37M–
FY2019Dec 31, 2019-$11.25M–
FY2018Dec 31, 2018-$3.91M–
FY2017Dec 31, 2017-$14.98M–
FY2016Dec 31, 2016-$19.25M–
FY2015Dec 31, 2015-$16.67M–
FY2014Dec 31, 2014-$23.53M–
FY2013Dec 31, 2013-$20.96M–
FY2012Dec 31, 2012-$33.76M–
FY2010Jun 30, 2010-$17.80M–
FY2009Jun 30, 2009-$16.17M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$434.00K–
Q1 FY2026Mar 31, 2026-$8.06M–
Q4 FY2025Dec 31, 2025$22.42M+21.3%
Q3 FY2025Sep 30, 2025$3.45M–
Q2 FY2025Jun 30, 2025-$2.03M–
Q1 FY2025Mar 31, 2025-$12.79M–
Q4 FY2024Dec 31, 2024$18.48M+45.1%
Q3 FY2024Sep 30, 2024-$2.47M–
Q2 FY2024Jun 30, 2024-$6.03M–
Q1 FY2024Mar 31, 2024-$5.46M–
Q4 FY2023Dec 31, 2023$12.73M+109.2%
Q3 FY2023Sep 30, 2023-$5.06M–
Q2 FY2023Jun 30, 2023-$5.96M–
Q1 FY2023Mar 31, 2023-$8.18M–
Q4 FY2022Dec 31, 2022$6.09M+46.9%
Q3 FY2022Sep 30, 2022-$6.79M–
Q2 FY2022Jun 30, 2022-$9.08M–
Q1 FY2022Mar 31, 2022-$7.27M–
Q4 FY2021Dec 31, 2021$4.14M-66.3%
Q3 FY2021Sep 30, 2021-$4.96M-241.1%
Q2 FY2021Jun 30, 2021-$3.73M–
Q1 FY2021Mar 31, 2021-$3.31M–
Q4 FY2020Dec 31, 2020$12.29M+33.4%
Q3 FY2020Sep 30, 2020$3.52M+13.6%
Q2 FY2020Jun 30, 2020-$8.36M–
Q1 FY2020Mar 31, 2020-$5.08M–
Q4 FY2019Dec 31, 2019$9.21M+53.6%
Q3 FY2019Sep 30, 2019$3.10M–
Q2 FY2019Jun 30, 2019-$20.20M–
Q1 FY2019Mar 31, 2019-$3.36M–
Q4 FY2018Dec 31, 2018$6.00M+403.4%
Q3 FY2018Sep 30, 2018-$1.34M–
Q2 FY2018Jun 30, 2018-$4.25M–
Q1 FY2018Mar 31, 2018-$4.32M–
Q4 FY2017Dec 31, 2017$1.19M0.0%
Q3 FY2017Sep 30, 2017-$4.03M–
Q2 FY2017Jun 30, 2017-$2.52M–
Q1 FY2017Mar 31, 2017-$9.62M–
Q4 FY2016Dec 31, 2016$1.19M–
Q3 FY2016Sep 30, 2016-$6.38M–

More Vericel figures

See a number that looks wrong?